Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
MENINGO-COCCAL POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE bulk supplier for pharma manufacturers

Meningo-Coccal Polysaccharide Diphtheria Toxoid Conjugate 4 mcg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 4 mcg

Reference Brands: Menactra (USA), Menveo (USA/EU), Nimenrix (LATAM)

Category: Vaccines

Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the bacteria.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Meningococcal infection can cause life-threatening illnesses, such as meningococcal meningitis, which affects the brain, and meningococcemia, which affects the blood. Some persons with meningococcal meningitis and/or meningococcemia may die. The rate of these diseases peak in adolescence and early adulthood and are more likely to occur in persons with certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.

Meningo-Coccal Polysaccharide Diphtheria Toxoid Conjugate — third party manufacturing & bulk supply

Meningo-Coccal Polysaccharide Diphtheria Toxoid Conjugate 4 mcg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Indicative minimum order quantity

Meningo-Coccal Polysaccharide Diphtheria Toxoid Conjugate is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Meningo-Coccal Polysaccharide Diphtheria Toxoid Conjugate listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Meningo-Coccal Polysaccharide Diphtheria... →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine is used to prevent meningococcal disease caused by Neisseria meningitidis. It helps protect against serious infections such as meningitis and bloodstream infections that can lead to severe complications or death.

This vaccine is made from purified capsular polysaccharides of Neisseria meningitidis bacteria that are chemically linked to diphtheria toxoid protein. The conjugation improves the immune response, particularly in children and adolescents.

Common trade names include Menactra, Menveo, and Nimenrix.

This vaccine is manufactured by pharmaceutical companies such as Sanofi Pasteur, GlaxoSmithKline (GSK), and Pfizer.

The generic name is meningococcal polysaccharide diphtheria toxoid conjugate vaccine.

Brand names include Menactra, Menveo, and Nimenrix.

This vaccine is manufactured in several countries including the United States, Italy, Belgium, and other regions depending on the manufacturer.Menactra

Related Products

Respiratory Syncytial Virus Mrna Vaccine

Strength:
0.5 mL

Form: injection (prefilled syringe)

Reference Brands: mRESVIA (USA/EU)

View Details
Inactivated Vaccines

Strength:
Dose and concentration depend on formulations

Form: Injectable suspension (IM administration), Lyophilized powder for reconstitution

Reference Brands: Sinovac Coronavac. Covaxin(EU)

View Details
Viral Vector Vaccines

Strength:
0.5 mL

Form: Intramuscular injectable suspension (IM)

Reference Brands: US: Johnson & Johnson’s Janssen (Jcovden)

View Details
Mrna-Based Vaccines

Strength:
30 µg and 100 µg

Form: Injectable suspension

Reference Brands: Comirnaty, Spikevax(US)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.